| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Division of Critical Care Neurology (Drs. Claassen and Mayer, J.E. Bates), and the Comprehensive Epilepsy Center (Drs. Hirsch and Emerson and T.B. Thompson), Neurological Institute, Columbia University College of Physicians and Surgeons, New York, NY.
Address correspondence and reprint requests to Dr. S.A. Mayer, Division of Critical Care Neurology, Neurological Institute, 710 W. 168 St., Unit 39, New York, NY 10032; e-mail: sam14{at}columbia.edu
Background:— Although cIV-MDZ has emerged as a popular alternative to barbiturate therapy for refractory status epilepticus (RSE), experience with its use for this indication is limited.
Objective:— To evaluate the efficacy of continuous intravenous midazolam (cIV-MDZ) for attaining sustained seizure control in patients with RSE.
Methods:— The authors reviewed 33 episodes of RSE treated with cIV-MDZ in their neurologic intensive care unit over 6 years. All patients were monitored with continuous EEG (cEEG). MDZ infusion rates were titrated to eliminate clinical and EEG seizure activity; cIV-MDZ was discontinued once patients were seizure-free for 24 hours. Acute treatment failures (seizures 1 to 6 hours after starting cIV-MDZ), breakthrough seizures (after 6 hours of therapy), post-treatment seizures (within 48 hours of discontinuing therapy), and ultimate treatment failure (frequent seizures that led to treatment with pentobarbital or propofol) were identified.
Results:— All patients were in nonconvulsive SE at the time cIV-MDZ was started; the mean duration of SE before treatment was 3.9 days (range 0 to 17 days). In addition to benzodiazepines, 94% of patients had received at least two antiepileptic drugs (AED) before starting cIV-MDZ. The mean loading dose was 0.19 mg/kg, the mean maximal infusion rate was 0.22 mg/kg/h, and the mean duration of cIV-MDZ therapy was 4.2 days (range 1 to 14 days). Acute treatment failure occurred in 18% (6/33) of episodes, breakthrough seizures in 56% (18/32), post-treatment seizures in 68% (19/28), and ultimate treatment failure in 18% (6/33). Breakthrough seizures were clinically subtle or purely electrographic in 89% (16/18) of cases and were associated with an increased risk of developing post-treatment seizures (p = 0.01).
Conclusions:— Although most patients with RSE initially responded to cIV-MDZ, over half developed subsequent breakthrough seizures, which were predictive of post-treatment seizures and were often detectable only with cEEG. Titrating cIV-MDZ to burst suppression, more aggressive treatment with concurrent AED, or a longer period of initial treatment may reduce the high proportion of patients with RSE who relapse after cIV-MDZ is discontinued.
This article has been cited by other articles:
|
|
 |
|
  D. J. Costello and A. J. Cole Treatment of Acute Seizures and Status Epilepticus J Intensive Care Med, November 1, 2007; 22(6): 319 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Claassen, N. Jette, F. Chum, R. Green, M. Schmidt, H. Choi, J. Jirsch, J. A. Frontera, E. S. Connolly, R. G. Emerson, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage Neurology, September 25, 2007; 69(13): 1356 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Chung, N. C. Wang, and D. M. Treiman Comparative Efficacy and Safety of Antiepileptic Drugs for the Treatment of Status Epilepticus Journal of Pharmacy Practice, April 1, 2007; 20(2): 137 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 J. C. D. Brevoord, K. F. M. Joosten, W. F. M. Arts, R. W. van Rooij, and M. de Hoog Status Epilepticus: Clinical Analysis of a Treatment Protocol Based on Midazolam and Phenytoin J Child Neurol, June 1, 2005; 20(6): 476 - 481. [Abstract] [PDF]
|
|
|
|
|
|
J. C. D. Brevoord, K. F. M. Joosten, W. F. M. Arts, R. W. van Rooij, and M. de Hoog Status Epilepticus: Clinical Analysis of a Treatment Protocol Based on Midazolam and Phenytoin J Child Neurol, June 1, 2005; 20(6): 476 - 481. [Abstract] [PDF]
|
|
|
|
 |
|
 P. E. Marik and J. Varon The Management of Status Epilepticus Chest, August 1, 2004; 126(2): 582 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Mirsattari, M. D. Sharpe, and G. B. Young Treatment of Refractory Status Epilepticus With Inhalational Anesthetic Agents Isoflurane and Desflurane Arch Neurol, August 1, 2004; 61(8): 1254 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Claassen, S. Peery, K.T. Kreiter, L.J. Hirsch, E.Y. Du, E.S. Connolly, and S.A. Mayer Predictors and clinical impact of epilepsy after subarachnoid hemorrhage Neurology, January 28, 2003; 60(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Koul, A. Chako, H. Javed, and Kassim Al Riyami Eight-Year Study of Childhood Status Epilepticus: Midazolam Infusion in Management and Outcome J Child Neurol, December 1, 2002; 17(12): 907 - 909. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Mayer, J. Claassen, J. Lokin, F. Mendelsohn, L. J. Dennis, and B.-F. Fitzsimmons Refractory Status Epilepticus: Frequency, Risk Factors, and Impact on Outcome Arch Neurol, February 1, 2002; 59(2): 205 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 IV Midazolam Confers Minimal Benefit in Refractory Status Epilepticus Journal Watch Neurology, January 24, 2002; 2002(124): 6 - 6. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
